Anebulo Pharmaceuticals, Inc. (ANEB) has disclosed a new risk, in the Share Price & Shareholder Rights category.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Anebulo Pharmaceuticals, Inc. faces a significant business risk as it seeks stockholder approval for a reverse stock split, part of a plan to go private and delist from the Nasdaq Stock Market. This move could lead to reduced transparency and liquidity, as the company would no longer file regular reports with the SEC, making it harder for investors to access information. The potential delisting and deregistration may also decrease the stock’s value due to limited trading options, primarily through private sales or the OTC market, if available. The decision to proceed with the reverse stock split and subsequent actions rests with the board, which may abandon the plan if deemed not in the company’s best interests.
Overall, Wall Street has a Hold consensus rating on ANEB stock based on 1 Hold.
To learn more about Anebulo Pharmaceuticals, Inc.’s risk factors, click here.